scispace - formally typeset
Open AccessJournal ArticleDOI

Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time

Reads0
Chats0
TLDR
The findings indicate that DDAVP might be given when biopsies or other surgical procedures must be carried out in patients with prolonged BT, however, the compound is often ineffective in Patients with thrombocytopenia or congenital platelet dysfunction.
About
This article is published in Blood.The article was published on 1986-04-01 and is currently open access. It has received 196 citations till now. The article focuses on the topics: Desmopressin & Bleeding time.

read more

Citations
More filters
Journal ArticleDOI

Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years

TL;DR: In 1977, DESMOPRESSIN (1-deamino-8-Darginine vasopressin, abbreviated DDAVP), a derivative of the antidiuretic hormone, was used for the first time to treat patients with hemophilia A and von Willebrand disease (vWD).
Journal ArticleDOI

Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders [see comments]

TL;DR: There is evidence from controlled clinical trials that DDAVP can reduce blood loss and transfusion requirements for hemostatically normal individuals undergoing spinal fusion surgery and for patients undergoing cardiopulmonary bypass surgery.
Journal ArticleDOI

Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders.

TL;DR: Desmopressin (1-deamino-8-d -arginine vasopressin, abbreviated DDAVP) is a synthetic analogue of the antidiuretic hormone larginines vasopressesin this paper.
Journal ArticleDOI

Guideline on the management of bleeding in patients on antithrombotic agents.

TL;DR: The objective of this document is to guide healthcare professionals on the management of patients receiving antithrombotic drugs who experience significant bleeding or who require emergency surgery or an invasive procedure.
References
More filters
Journal ArticleDOI

Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium.

TL;DR: Evidence is presented that factor VIII–VWF binds to subendothelium of human arteries and that subendOThelium-bound factor VIII-Von Willebrand factor complex mediates the platelet adhesion.
Journal ArticleDOI

Multimeric Composition of Factor VIII/von Willebrand Factor Following Administration of DDAVP: Implications for Pathophysiology and Therapy of von Willebrand's Disease Subtypes

TL;DR: It is suggested that complete hemostatic correction following DDAVP can be routinely expected only in type I von Willebrand's disease, and only if factor VIII/vonWillebrand factor can be raised to normal levels.
Journal ArticleDOI

Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin.

TL;DR: It is indicated that in male subjects the prolonged template bleeding time after aspirin is not the consequence of selective inhibition of platelet production of thromboxane, and there is little difference between the initial inhibitory response of Platelet cyclooxygenase and that of vessel-wall cyclo Oxygenase to these doses of aspirin.
Journal ArticleDOI

Shortening of bleeding time by 1-deamino-8-d-arginine vasopressin in various bleeding disorders

TL;DR: Normal haemostatis was achieved with DDAVP plus epsilon-aminocaproic acid and no blood product support during operations in 18 patients with bleeding disorders.
Journal ArticleDOI

Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.

TL;DR: It is concluded that ticlopidine induces a thrombasthenic state in normal platelets without affecting the glycoprotein IIb-IIIa complex quantitatively.
Related Papers (5)